SKB118 Injection in Advanced Solid Tumors

Starting soon · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors

In brief

This is a phase 1/2 clinical study to evaluate the safety and efficacy of SKB118 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.

Key facts

Study ID

NCT07586943

Run by

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

People needed

332

Starts

2026-06-01

Expected to finish

2030-12-01

Last updated by the study team

2026-05-14

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants voluntarily joined this study and signed an informed consent form.
• The age at the time of signing the informed consent form must be between 18 and 75 years.
• Participants with histologically or cytologically confirmed advanced solid tumors who have failed standard therapy, have no standard therapy available, or are intolerant to standard therapy.
• Participants should provide tumor tissue samples for biomarker testing as much as possible.
• Researchers evaluated based on Response Evaluation Criteria in Solid Tumors(RECIST) Version 1.1 that there is at least one measurable lesion present.
• Eastern Cooperative Oncology Group (ECOG) score is 0 or 1.
• Expected survival period ≥ 12 weeks.
• Participants have sufficient bone marrow, liver, kidney, and coagulation functions.
• Male and female participants must agree to use highly effective contraceptive methods during the study period.

You may not qualify if…

• Participants known to have meningeal metastasis, brainstem metastasis, spinal cord metastasis and/or compression, and active central nervous system (CNS) metastasis.
• Patients with other malignant tumors within 3 years before the first administration.
• There are serious heart or vascular diseases or high-risk factors present.
• According to researchers' judgment, it is an uncontrollable systemic disease.
• There are pleural effusion, pericardial effusion, or ascites with clinical symptoms or requiring repeated drainage (>1 time/week).
• History of interstitial lung disease or non infectious pneumonia.
• There are other lung diseases that may interfere with drug-related pulmonary toxicity.
• There is a risk of developing esophagotracheal fistula or esophageal pleural fistula, or tumor invasion or compression of surrounding important organs and blood vessels accompanied by related clinical symptoms.
• Screening imaging shows that the tumor encases important blood vessels or exhibits obvious necrosis or cavities, and the investigator determines that study enrollment would pose a risk of bleeding.
• Previous or concurrent gastrointestinal perforation, surgical and wound healing complications, and bleeding events.
• The toxicity of previous anti-tumor treatments has not been relieved, defined as the toxicity has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0 grade 0 or 1.
• Have experienced ≥ Grade 3 immune-related adverse events (irAEs) during prior immunotherapy.
• Serious infection occurred within 4 weeks before the first administration.
• Active hepatitis B or C, or simultaneous infection with Hepatitis B virus(HBV) and Hepatitis C virus(HCV).
• Human immunodeficiency virus (HIV) test is positive or there is a history of acquired immunodeficiency syndrome (AIDS); Known active syphilis infection.
• Known active pulmonary tuberculosis.
• Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation.
• History of allergies to any components of SKB118 injection or severe hypersensitivity reactions to other monoclonal antibodies.
• Having an active autoimmune disease that required systemic treatment within the past two years.
• Active or prior history of confirmed inflammatory bowel disease.
• Currently using or having recently used aspirin therapy.
• Received oral or parenteral anticoagulants or thrombolytic agents within 2 weeks prior to the first dose.
• Previous treatment with antibodies or drugs targeting T-cell co- stimulation or checkpoint pathways, as well as cell therapy.
• Received chemotherapy, immunotherapy, biological therapy, or other large molecule anti-tumor drugs within 4 weeks before the first administration.
• Within 6 months prior to the first administration, lung lesions received radiation therapy with a total dose greater than 30 Gray.

Where it is running

• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.